Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
about
Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidateAn optogenetic toolbox designed for primatesGene therapy: progress and predictionsPerinatal systemic gene delivery using adeno-associated viral vectorsCurrent prospects and challenges for epilepsy gene therapyStructural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9Structure of adeno-associated virus-2 in complex with neutralizing monoclonal antibody A20The structure of AAVrh32.33, a novel gene delivery vectorGene therapy for hemophiliaGene therapy in an era of emerging treatment options for hemophilia BDurable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopesStructure of neurotropic adeno-associated virus AAVrh.8.Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene TransferGene therapy for metachromatic leukodystrophy.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy.Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapyReengineered AAV vectors: old dog, new tricks.Systemic gene delivery to the central nervous system using Adeno-associated virus.Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Gene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler DiseaseThe current status of gene therapy for Parkinson's diseasePeptide ligands incorporated into the threefold spike capsid domain to re-direct gene transduction of AAV8 and AAV9 in vivoNovel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors.Gene transfer to the CNS using recombinant adeno-associated virusEnhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity.Directed evolution of novel adeno-associated viruses for therapeutic gene delivery.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disordersAdeno-associated virus: fit to serveAdeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice.Pseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis.Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.Intraganglionic AAV6 results in efficient and long-term gene transfer to peripheral sensory nervous system in adult rats.Pre-immunization with an intramuscular injection of AAV9-human erythropoietin vectors reduces the vector-mediated transduction following re-administration in rat brainRescuing the failing heart by targeted gene transferPreclinical safety evaluation of a recombinant AAV8 vector for X-linked retinoschisis after intravitreal administration in rabbits.
P2860
Q24288709-F0FDB453-26EE-4518-BFDF-76523F787B8EQ24623252-EB3BAF55-89C4-4904-9BE3-798992DCFA1EQ26772109-862FE880-E5C1-4C80-BD86-7B67DDB3DC33Q26852989-DDED9DB7-BEF8-42AF-A553-C4471B4E22D6Q27002627-9A1714D0-1D6A-4FB0-BA05-F390B3D46EA5Q27678476-365471CB-CA77-4E42-B781-25611808AB91Q27681034-B3223BC9-A3D2-4F6B-A568-308173344FAEQ27682946-9740B2AB-8D07-4785-B923-1A551A8A410CQ28081911-8E49C0E2-6D9F-48FF-A5B1-7D0E2DE23E03Q28087557-5AC0EEBB-D2BA-4EED-BDF4-723227BBCE12Q28603888-CCB5C254-DD47-4620-A50E-4C9E7455C946Q30152836-3F525923-7D46-431C-B690-2398B21D3493Q30152887-4BD15A61-A5B1-438A-97ED-CC2FD190AE44Q30357745-F4B3B7FD-C908-4E0B-8713-92982B76E135Q30490945-7A227A17-34F9-448F-AF70-CD63FCC56F63Q30539199-4D9350C8-A67E-4F28-B735-C7B7C77FEB7BQ30541880-1B8EF8A4-3DE2-4A93-8165-6DFE5F9D7230Q33591886-E8D17238-8C4B-4248-9108-2D9FE812F856Q33695674-DC40325B-4D7D-4EBE-9882-23017FAA04C2Q33881920-B8DA5E0D-6DE7-4131-91A9-F9FB63853324Q33902499-B599C90A-6DE9-47D3-824B-BB1F7BC333A7Q33926944-6E4914DE-18A6-406F-9C86-997707C6E9A8Q33974900-118C9959-B2C0-4810-ADB8-561DC9394796Q33979379-702903FF-1A05-4EBA-8BDE-0D00ADC2B0F5Q33995646-F1A1CDAF-91F9-4366-886F-8F7EB6FF1B3CQ34034500-03F72E4D-D5D5-44DC-AE1C-75C2860C1B36Q34055904-CE4FDBFC-C1D4-4EAD-93FA-14AB33AA2328Q34069571-BD765369-1C79-44BC-AA8F-2C37EFC141DAQ34188892-A8E1BDE3-F526-4421-A4D7-C3221EC01BE5Q34205620-731F7AFB-50A5-4C58-B65B-EE5A08DB1783Q34332817-82E9F5A6-C5E6-497B-BE48-A2D9535AF28BQ34370111-E34250A7-59EE-4006-A5F9-13F0FDBBD9A4Q34384998-F78181F6-FE13-40A2-A82B-5EEB744494E6Q34399258-42A5A9E3-EAF1-417C-BA86-44FE01309976Q34499502-D2831832-F0C5-42B3-B9EE-03CC7D08D909Q34566454-A98D9FC3-4FDC-4359-8AB0-B8905D101460Q34684229-D7F32290-2575-4C6E-B0B8-C0E29A22A981Q34718452-583527D9-D1B4-4749-BD55-374C3CC9DC27Q34757960-F571B239-9D1E-4688-BD20-54A0907BE59CQ34768369-27646527-2097-4012-A620-2F532A02E6EA
P2860
Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@en
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@nl
type
label
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@en
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@nl
prefLabel
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@en
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@nl
P2093
P356
P1433
P1476
Prevalence of serum IgG and ne ...... ene therapy using AAV vectors.
@en
P2093
Carole Masurier
Christian Leborgne
Marie Françoise Montus
Olivier Benveniste
Philippe Veron
Sylvie Boutin
Virginie Monteilhet
P304
P356
10.1089/HUM.2009.182
P577
2010-06-01T00:00:00Z